



FFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elisabetta Bianchi et al.	Confirmation No:	TBA
Serial No.:	10/583,491	Case No.:	ITR0054P
Filed:	June 15, 2006	Art Unit:	TBA
For:	A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGATE WITH A HIGH IMMUNOGENICITY		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Response to Notification of Defective Response

Sir:

In response to the Notification of Defective Response mailed November 19, 2008, submitted herewith is a Sequence Listing (in computer readable and written form) and a Statement In Accordance With 37 CFR §§ 1.821-1.825.

No fee is believed to be due. However, the Commissioner is hereby authorized to charge any additional fees which may be required to deposit account 13-2755.

Respectfully submitted,

Dated: 25 November 2008

By:

Melissa B. Wenk
Reg. No. 53,759
Attorney for Applicants

Correspondence Address:

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-2756 Telephone
(732) 594-7790 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Douglas P. Smith Date 11/25/2008



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elisabetta Bianchi et al.		Confirmation No:	TBA
Serial No.:	10/583,491		Case No.:	ITR0054P
Filed:	June 15, 2006		Art Unit:	TBA
For:	A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGATE WITH A HIGH IMMUNOGENICITY			Examiner: TBA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT IN ACCORDANCE WITH 37 CFR §§ 1.821-1.825

Sir:

Enclosed is a Sequence Listing in computer readable and written form. I hereby state that the information recorded in computer readable form of the Sequence Listing is identical to the written form of the Sequence Listing.

Respectfully submitted,

Dated: 25 November 2008

By:



Melissa B. Wenk
Reg. No. 53,759
Attorney for Applicants

Correspondence Address:

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-2756 Telephone
(732) 594-7790 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.


By ____ Date 11/25/2008



SEQUENCE LISTING

<110> Elisabetta Bianchi
Antonello Pessi
Marco Finotto
Paolo Ingallinella

<120> A METHOD TO MAKE A PEPTIDE-CARRIER
CONJUGATE WITH A HIGH IMMUNOGENICITY

<130> ITR0054P

<140> 10/583,491
<141> 2006-06-15

<150> 60/530,867
<151> 2003-12-18

<150> PCT/EP2004/014160
<151> 2004-12-14

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 1
Cys Gly Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly
1 5 10 15
Phe Ile Glu Asn Gly Asn His
20

<210> 2
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 2
Ala Cys Gly Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala
1 5 10 15
Gly Phe Ile Glu Asn Gly Glu His
20

<210> 3
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 3
Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile
1 5 10 15
Glu Asn Gly Cys Asn His
20

<210> 4
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 4
Ser Glu Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly
1 5 10 15
Phe Ile Glu Asn Gly Cys His
20

<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 5
Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln
1 5 10 15
Leu Cys Asn His
20

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 6
Ser Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg
1 5 10 15
Gln Leu Cys Asn His
20

<210> 7
<211> 29
<212> PRT
<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 7

Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly
1				5					10				15		
Met	Ile	Asp	Gly	Gly	Cys	Gly	Lys	Lys	Lys	Lys	Asn	His			
		20					25								

<210> 8

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 8

Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly
1				5					10				15		
Met	Val	Asp	Gly	Cys	Glu	His									
		20													

<210> 9

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 9

Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Cys	Glu	His
1				5					10				15		

<210> 10

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 10

Ala	Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Cys	Glu
1					5					10				15	
His															

<210> 11

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 11
Ser Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Cys Glu
1 5 10 15
His